NCT01271894View on ClinicalTrials.gov

The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)

PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
HIV Infection
Interventions
DRUG

Efavirenz

600 mg once daily; given as 3 x 200 mg once

DRUG

Efavirenz

400 mg once daily; given as 2 x 200 mg + 1 x placebo

Trial Locations (4)

Unknown

Hospital J.M. Ramos Mejia, Buenos Aires

Desmond Tutu HIV Foundation, Cape Town

Thai Red Cross-AIDS Research Centre, HIV-NAT Research Collaboration, Bangkok

Chelsea and Westminister Hospital, London

Sponsors

Lead Sponsor

Kirby Institute
All Listed Sponsors
collaborator

Chelsea and Westminster NHS Foundation Trust

OTHER

lead

Kirby Institute

OTHER_GOV

NCT01271894 - The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK) | Biotech Hunter | Biotech Hunter